Medication topics
Risankizumab articles focused on access, approvals, label changes, coverage, and availability for IBD treatment.
11 articles
There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
A subcutaneous induction option for SKYRIZI could let people with Crohn’s start and continue treatment with injections instead of beginning with an IV infusion, which may affect convenience, time in clinic, and infusion...
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.
A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...
Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from firstwordpharma.com.
A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.
An FDA approval means another biologic option is available for Crohn’s disease, which could affect treatment choices and insurance coverage. The approval also signals pharma competition and pipeline activity that may...
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
